Andrew Smith | Authors


Navigating Opioids and Other Strategies for Managing Cancer Pain

October 02, 2021

Up to 60% of patients undergoing active treatment and a third of cancer survivors report significant pain stemming either from their cancer itself or their cancer treatments. The most common treatment for significant cancer- related pain is opioid medication.

Unique Immunotherapy Combinations Provide an Optimistic Outlook in Early Urothelial Carcinoma Trials

March 11, 2019

Ongoing research seeks to boost objective response rates in urothelial cancer by developing biomarkers to predict which immune checkpoint inhibitors a patient is most likely to respond to and by testing these in combination with each other and other treatment types to increase both the number and duration of responses.

Expansion Cohorts Guidance Balances Drug Development With Safety, Rigor

December 26, 2018

New draft guidelines from the FDA endorse the use of multiple expansion cohorts in first-in-human clinical trials as a means of speeding lifesaving medications to market, but the document warns that the difficulties and dangers of using such complex studies so early in the testing process necessitate unusually careful design and oversight.

Trial Investigators Discuss FDA Draft Guidance on Master Protocols

December 01, 2018

Complex drug trials that use a single protocol to test either 1 agent against multiple cancers or multiple agents against 1 cancer can make drug testing faster, cheaper, and more informative, particularly when those trials use the data to constantly improve protocols.

Research Shows Growing Attention Toward Gut Microbiome's Role in Immunotherapy Response

June 18, 2018

Researchers’ understanding of why patients with cancer do or do not respond to treatment with immune checkpoint inhibition is constantly evolving, with new developments in innate and adaptive immunity, the tumor microenvironment, and more changing the way that immunotherapy is viewed and used. Many researchers are now pointing to the effect that gut microbiota have on patients’ response to checkpoint inhibitors and its implications for the treatment of patients receiving immunotherapy.